Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 6/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973478 | 0.90 | BTN3A1 (0.52) | BTN3A1ELANEPRTN3TP53KLK1 | |
| SCHEMBL22066002 | 0.89 | BTN3A1 (0.38) | BTN3A1ELANEPRTN3CTSLCTSB | |
| SCHEMBL18973563 | 0.89 | BTN3A1 (0.47) | BTN3A1ELANEPRTN3TP53CTSL | |
| SCHEMBL18973555 | 0.86 | BTN3A1 (0.45) | BTN3A1ELANEPRTN3CTSLCTSB | |
| SCHEMBL18973573 | 0.85 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3TP53KLK1 | |
| SCHEMBL22066286 | 0.85 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3TP53KLK1 | |
| SCHEMBL22066288 | 0.85 | BTN3A1 (0.50) | BTN3A1ELANEPRTN3TP53CTSL | |
| SCHEMBL22065042 | 0.83 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3TP53KLK1 | |
| SCHEMBL22065701 | 0.82 | BTN3A1 (0.53) | BTN3A1ELANEPRTN3TP53KLK1 | |
| SCHEMBL24505391 | 0.82 | BTN3A1 (0.60) | BTN3A1ELANEPRTN3TP53KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20210009625-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES | LAURUS LABS PRIVATE LTD (IN) | 2021-01-14 | — | — | US | disclosed |
| US-10774104-B2 | Diastereoselective synthesis of phosphate derivatives | LAURUS LABS PRIVATE LTD (IN) | 2020-09-15 | — | — | US | disclosed |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20200181190-A1 | SYNTHESIS OF 3'-DEOXYADENOSINE-5'-O-[PHENYL(BENZYLOXY-L-ALANINYL)]PHOSPHATE (NUC-7738) | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774104-B2 | Diastereoselective synthesis of phosphate derivatives | TYMP, PNP, DPYD | BTN3A1 4678/4885ELANE 4526/4885PRTN3 1874/4885 |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | BTN3A1 4531/4885ELANE 4653/4885PRTN3 1013/4885 |
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PNP, NTPCR, TYMP | BTN3A1 2948/4885ELANE 3870/4885PRTN3 724/4885 |
| US-20210009625-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES | TYMP, PNP, DPYD | BTN3A1 4228/4885ELANE 4731/4885PRTN3 2082/4885 |
| US-20200181190-A1 | SYNTHESIS OF 3'-DEOXYADENOSINE-5'-O-[PHENYL(BENZYLOXY-L-ALANINYL)]PHOSPHATE (NUC-7738) | PNP, NT5C2, DUT | BTN3A1 3995/4885ELANE 3725/4885PRTN3 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.